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ABBREVIATIONS 
 
AB  antibody 
Ang-1  angiopoietin 1 
bFGF  basic fibroblast growth factor  
cDNA   complementary DNA 
CD11b  cluster of differentiation (cluster of designation) 11b 
CD90  cluster of differentiation 90 = Thy-1 (a fibroblast marker) 
CM   conditioned media  
CM-IFM conditioned media harvested from explant cultures of interface 
membrane 
CM-NSy conditioned media harvested from explant cultures of normal synovial 
tissue  
CM-RASy  conditioned media harvested from explant cultures of rheumatoid 
synovial tissue  
c-myc  oncogene 
COX-1 cyclooxygenase 1 
COX-2 cyclooxygenase 2 
CO2   carbon dioxide 
Ct   threshold cycle  
DMEM Dulbecco’s modified minimal essential medium 
DNA   deoxyribonucleic acid 
ELISA  enzyme-linked immunosorbent assay 
FBS  fetal bovine serum 
FGF-R  fibroblast growth factor receptor  
FITC  fluorescein isothiocyanate 
GAPDH  glyceraldehyde-6-phosphate dehydrogenase housekeeping gene 
hAngio-1 human Riboquant Multiprobe RPA template 
hCK26  human Riboquant Multiprobe RPA template 
hCK3  human Riboquant Multiprobe RPA template 
hCK4  human Riboquant Multiprobe RPA template 
hCR4  human Riboquant Multiprobe RPA template 
hCR5  human Riboquant Multiprobe RPA template 
hCR6  human Riboquant Multiprobe RPA template 
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IFM   interface membrane  
IFM-Fb interface membrane fibroblast 
IFN-γ  interferon-γ  
IL-1α   interleukin-1α 
IL-1β   interleukin-1β 
IL-1RI  IL-1 receptor type I  
IL-4  interleukin-4 
IL-6  interleukin-6 
IL-8  interleukin-8 
IP-10   interferon-γ-inducible 10-kDa protein = CXCL-10  
(a CXC chemokine)  
LIF  leukemia inhibitory factor  
L32  housekeeping gene 
mAb   monoclonal antibody 
MCP-1 monocyte chemoattractant protein 1 
M-CSF macrophage colony stimulating factor 
MMP-1 matrix metalloproteinase-1 (collagenase) 
mRNA  messenger ribonucleic acid 
NF-KB  nuclear factor kappa-light-chain-enhancer of activated B cells 
NSy  fresh normal synovial tissue  
OA   osteoarthritis 
OPG   osteoprotegerin, osteoclastogenesis inhibitory factor  
(a decoy receptor of RANKL) 
OSM  oncostatin M  
PAGE   polyacrylamide gel electrophoresis 
PBS  phosphate buffered salt solution 
PCR   polymerase chain reaction 
QRT-PCR  reverse transcription real-time quantitative polymerase chain reaction 
RA  rheumatoid arthritis 
RANKL receptor activator of nuclear factor kappa-B ligand  
(osteoprotegerin ligand) 
RANTES  regulated upon activation normally T-cell expressed and secreted  
(a CXC chemokine) 
RASy   rheumatoid synovial tissue 
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rhRANKL  recombinant human RANKL   
RNA   ribonucleic acid 
RPA  RNase protection assay  
SCF  stem cell factor  
SDS   sodium duodecyl sulfate 
SEM   standard error of the mean 
SYBR Green  asymmetrical cyanine dye (a nucleic acid stain)    
TGF-β1  transforming growth factor-β1 
TGF-βRI TGF-β receptor type I 
Thy-1  thymocyte antigen 1 (a fibroblast surface marker) 
Ti   titanium 
TJA  total joint arthroplasty  
TNF-α  tumor necrosis factor-α 
TNFR p55 tumor necrosis factor receptor p55  
TNFR p75  tumor necrosis factor receptor p75 
TRAP  tartarate-resistant acid phosphatase 
Untr  untreated 
UTP   uridine 5’-triphosphate 
VEGF  vascular endothelial growth factor 
32P   phosphorus-32 (an isotope, used for labeling nucleic acids) 
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INTRODUCTION 
 
Periprosthetic osteolysis following total joint arthroplasty (TJA) is a major clinical 
problem in both cemented and cementless reconstructions (Fig. 1A). Aseptic failure 
of total joint prostheses has emerged as the major clinical problem interfering with 
the long-term success of these arthroplasties. Factors that interact to produce aseptic 
loosening can be divided into several independent processes, including those that 
involve mechanical factors, the material properties of the implants, and biological 
and host factors. 
One of the pathological features of periprosthetic osteolysis in failed TJAs is the 
formation of a pseudomembrane (interface membrane) at the bone/cement (Fig. 1B) 
or bone/prostheses interface (Fig. 1C). The importance of transformation of the 
material of an intact implant into particulate debris, and the capacity of the particles 
to induce a so-called foreign-body granulomatous response, is well established. 
Furthermore, the role of this tissue reaction in the inducement and perpetuation of 
peri-implant osteolysis has been recognized as a major problem contributing to 
aseptic loosening of total hip prostheses that have been inserted without cement. In 
fact, the hope that osteolysis would be eliminated was one reason for the 
development of implants that could be inserted without the use of cement. 
Debris from total hip arthroplasties falls into three basic categories: polyethylene 
debris from the acetabular component, polymethylmethacrylate debris associated 
with implants that have been inserted with cement, and metal debris. The release of 
these materials in particulate form is responsible for the invasion of inflammatory 
cells and the formation of granulomas. Similar lesions have been produced by the 
introduction of poorly resorbable particles into other organs; for example, silicosis 
has developed in people who have been exposed to coal dust. In these conditions, the 
interaction of the particles with monocyte macrophages and inflammatory 
polykaryons results in the release of soluble inflammatory mediators. These 
mediators then act directly on host tissues or on local connective-tissue cells to 
produce alterations in tissue architecture and function. When this process occurs 
within skeletal tissue, the reaction may lead to a disturbance in bone-remodeling, 
manifested as osteolysis. 
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In addition to stimulating an inflammatory process, particulate debris can result in 
wear of other components, by increasing the amount of polyethylene particles that is 
generated, if the debris is caught between the articular surfaces (e.g. femoral head 
and the acetabulum). 
Furthermore, metal debris may also have a toxic effect on cell function. This effect is 
mediated by the metal itself or by the corrosion or fretting corrosion products 
released by certain metals or metal alloys. 
 
 
 
Figure 1. A, Loosened total hip implant. Arrow shows osteolysis around the cup. B, Removed cup 
surrounded by a pseudomembrane. C, Aggressive tissue of an interface membrane. D, Explant culture. 
Approximately 0.5g wet synovial or interface membrane tissue was cultured in 2.5 ml DMEM 
containing 5% FBS. 
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The interface membrane (IFM) is a granulomatous tissue consisting predominantly 
of fibroblasts, macrophages, and foreign body giant cells (Fig. 2) (1-4).  
 
•fibrotic/fibrovascular zones macrophages,histiocytes
foreign-body giant cells
capillaries
fibroblasts
periprosthetic wear debris 
vascular endothelial cells
200 µm
 
 
Figure 2. Interface membrane (Hematoxylin and Eosin staining). 
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It is believed that particulate wear debris via phagocytosis activates cells which then 
proliferate and produce inflammatory mediators, such as TNF-α, IL-1β and IL-6. 
These “bone-resorbing” agents activate eventually all cell types in the IFM in either a 
paracrine or autocrine manner (Fig. 3) (3,5,6).  
 
autocrin
soluble-factor (cytokine) mediated
heterolog
cell-cell interaction
paracrin
direct contact (cognate)
homolog heterolog homolog
in a petri dish
monoculture
P > 3
 
Figure 3. Cell-cell interactions in vivo. Black scripts represent previous in vitro models. Black+blue 
scripts represent our improved in vitro model. Black+blue+red scripts would represent a perfect 
model. 
 
A large number of studies have shown that macrophages are activated by 
phagocytosed particles and produce inflammatory cytokines, which ultimately leads 
to osteoclastogenesis and increased bone resorption (4,7,8).  
  
Osteoblasts also phagocytose particles, and particulate phagocytosis significantly 
increases the secretion of TNF-α, IL-6, and the cell surface expression of RANKL 
(9,10), simultaneously suppressing procollagen E1[I] transcription (11) via the 
activation of NF-KB signaling (12,13).  
 
Information on the fibroblast (dominant cell type in the IFM) response to particle 
debris is less extensive (16-22). Thus, it still remains to be determined what role 
fibroblasts play in the pathogenesis of periprosthetic osteolysis associated with 
particle wear debris.  
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Several early studies dealt with the biological response to particulate debris. 
Jiranek et al. used two techniques that go beyond the scope of traditional 
histology to demonstrate directly the presence of specific cytokines that have been 
implicated in pathological resorption of bone and to localize these products to 
individual cell types. These authors used the techniques of in situ hybridization and 
immunohistochemistry. In situ hybridization permits identification of the individual 
cells expressing increased steady-state levels of mRNA for a given product. It has the 
advantage of being able to demonstrate the relationship of these cells to a known 
stimulus. Immunohistochemistry allows the differential identification of cell types 
that may have similar histological appearances. 
Jiranek et al. studied the interface membrane around total hip prostheses associated 
with evidence of aseptic loosening. Although in situ hybridization cannot be used to 
measure the actual release of cytokines, elevated steady-state levels of mRNA 
provide indirect evidence that these cytokines are being produced by certain cells. 
The association of these cytokines with cells expressing monocyte-macrophage 
phenotype provides direct evidence that these cells have an important role in the 
recognition of foreign material and the release of inflammatory mediators. In the 
model of Jiranek et al., these mediators modulated the activity of neighboring cells 
(including bone cells) that are responsible for mediating the focal osteolysis (14). 
Horowitz et al. demonstrated that phagocytosis of polymethylmethacrylate 
particles stimulates tumor necrosis factor, a cytokine that has been implicated in 
pathological resorption of bone. Horowitz et al. also established the importance of 
particle size in the determination of the pattern of the response. In addition, they 
demonstrated that the phagocytosis of cement is toxic to macrophages and results in 
cell lysis and death. They speculated that the release of mediators from dying cells 
may contribute to the capacity of cement to induce an inflammatory response. After 
cell lysis, the particulate debris may be released and thus re-enter the inflammatory 
cycle (15). 
Maloney et al., described the in vitro fibroblastic response to specific metallic 
debris. This work is important because it demonstrated the capacity of so-called 
facultative phagocytes to respond directly to metal wear particles by undergoing cell 
proliferation. This response may contribute to the development of the fibrous tissue 
reaction observed in peri-implant tissues. Relatively low concentrations of titanium, 
titanium-aluminum alloy, and chromium stimulated cell proliferation markedly, as 
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measured by the uptake of radioactive thymidine. The observation that cobalt was 
toxic at all concentrations and that it resulted in a decreased uptake of thymidine is 
consistent with the previously documented toxicity of this metal. At high 
concentrations, all of these particles were toxic. Maloney et al. speculated that 
metallic debris may stimulate the formation of the fibrous membrane around 
implants that were inserted without cement. Furthermore, they cited the hypothesis 
that this membrane may act as a conduit for the polyethylene debris that was 
generated at the articular surface to enter the space between the implant and the bone. 
They hypothesized that such polyethylene may contribute to a potential synergistic 
interaction between metallic and polymeric wear debris, which potentiates the 
production of factors that enhance osteolysis and accelerate loosening of total joint 
implants (16). 
Haynes et al. investigated the cellular responses to different metal-alloy wear 
particles of similar size on the release of the inflammatory mediators that have been 
implicated in bone resorption. The study was performed with macrophages, the cells 
that are probably the principal target for particle-mediated cell activation. 
These results complement the investigations of Maloney et al. and of Horowitz et al., 
and they demonstrate the specificity of the response in different cell types. Haynes et 
al. found that particles of cobalt-chromium were toxic to cells. Particles of titanium 
alloy resulted in minimum cell toxicity and were more likely to cause the release of 
inflammatory mediators that have been implicated in osteolysis, indicating that the 
pro-inflammatory effect of particles (the capacity to elicit one or more events 
involved in inflammation) may be as harmful as, or even more harmful than, the 
toxic effect. Thus, if a less toxic particle stimulates continuing synthesis and release 
of inflammatory mediators, it may, for example, have a marked biological effect in 
terms of the capacity to induce bone resorption. 
The high rate of failure of revision arthroplasties done without cement is believed, in 
part, to be related to the deficient bone stock that did not provide an adequate 
environment for the primary fixation with cement. Consequently, the potential for 
obtaining bone ingrowth with revision arthroplasties done without cement is less than 
that with primary arthroplasties done without cement (17).  
Turner et al. noted the importance of an environment with suitable osteogenic 
potential if fixation is to be obtained by bone ingrowth. They investigated various 
models, including autogenous bone graft and bone substitutes such as hydroxyapatite 
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β-tricalcium phosphate, with the goal of maximizing the osteogenic potential at the 
site of implantation (18). 
Horowitz et al., Maloney et al., and Haynes et al. used in vitro models based on cell 
culture to begin to define the factors that determine the outcome of metal and 
polymeric particle-cell interactions. These results extended the investigations in 
related fields and supplement the findings from earlier studies of materials used for 
orthopaedic implants. These previous investigations have helped to define the 
sequence of events associated with recognition and internalization of particles, 
although there are still many questions concerning the actual cellular and molecular 
processes by which these materials influence cell function.  
Yao et al. found that fibroblasts isolated from IFMs of patients with failed 
total joint replacements, when challenged with small-sized (<3 µm) titanium (Ti) 
particles, responded with enhanced expressions of collagenase, stromelysin and, to a 
lesser extent, tissue inhibitor of metalloproteinases (19). These responses were 
similar to that measured in fibroblast cultures of rheumatoid synovium, but more 
pronounced than in normal synovial fibroblasts in the same experimental condition.  
Moreover, particulate wear debris can directly activate fibroblasts to synthesize 
bone-resorbing metalloproteinases and possibly compounds which then suppress 
osteoblast functions critical for bone remodeling (11).  
 
Some of the fibroblast-derived factors may have an autocrine effect, or may alter the 
responsiveness of other cells (macrophages, osteoclasts) in the periprosthetic 
environment (22-24). Reciprocally, different cell types of IFM can phagocytose 
particles, produce various cytokines, chemokines, and growth factors in response to 
particulate stimulation, which then modify the fibroblast function (Fig. 3). 
 
The conclusions drawn from these in vitro studies must ultimately be tested against 
observations gleaned from appropriate in vivo experiments and careful correlations 
and analyses of retrieved clinical specimens.  
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To mimic the in vivo conditions of periprosthetic pathologic bone resorption as 
closely as possible, we stimulated interface membrane fibroblasts with titanium 
particles (Fig. 4) and/or conditioned media from interface membranes. In order to 
reproduce in vivo conditions, particles of approximately the same size distribution as 
the wear debris present in periprosthetic tissue (6,43–45) were used to stimulate 
fibroblasts. 
 
 
 
Figure 4. A, Untreated fibroblast culture (after 5 passages) isolated from an interface membrane. B, 
Same monoculture exposed to titanium particles overnight (0.075% [v/v]), and nonphagocytosed 
particles were washed out (light microscopy).  
 
In this study we focused on the fibroblast response measuring the expression of 
MCP-1, IL-6 (fibroblast activation markers), IL-1β, VEGF, RANKL and OPG in 
response to stimulation with Ti particles and/or the conditioned media of IFM of 
loosened TJAs.  
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THEORY 
 
Objectives 
The aim of this study was to investigate how the fibroblasts respond to 
stimulation with particulate wear debris and/or conditioned media (CM) obtained 
from pathologic tissues, and whether these activated fibroblasts express compounds 
which are involved in bone resorption. 
 
Methods 
Titanium particles (a “prototype” wear debris), conditioned media (CM) from 
explant cultures of synovial tissues, periprosthetic soft tissues (interface membranes; 
IFMs) and proinflammatory cytokines were used to stimulate fibroblasts. RNase 
protection assay (RPA) was used to measure altered gene expression, and 
enzymelinked immunosorbent assay, Western blot hybridization and flow cytometry 
to determine protein expressions by fibroblasts. Tartarate-resistant acid phosphatase 
staining was used to identify multinucleated osteoclast-like cells. 
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MATERIALS AND METHODS 
 
Particles and chemicals 
All chemicals, unless otherwise indicated, were purchased from Sigma 
Chemical Co. (St. Louis, MO) or Fisher Scientific (Chicago, IL). Commercially pure 
small-sized titanium (Ti) particles (<3 µm; Johnson Matthey, Danvers, MA) were 
sequentially treated with 25% nitric acid overnight at room temperature and 0.1M 
sodium hydroxide in 95% ethanol at 30OC for 10-12 hours three times (25), and then 
exhaustively washed with sterile, endotoxin-free phosphate buffered salt solution 
(PBS; pH 7.2). Endotoxin/lipopolysaccharide contamination of particles was 
excluded by using the high-sensitivity Limulus amoebocyte cell lysate assay 
(Biowhittaker, Walkersville, MD). Particles were autoclaved, sonicated and then 
sedimented in 10% human AB serum to remove a relatively larger size population of 
particles. The mean ± SD particle size was 1.42 ± 0.83 µm: 91% of these particles 
were smaller than 3 µm, and 72% smaller than 1 µm. Based upon the size 
distribution of these Ti particles (11,20), a 0.075% (volume/volume: v/v, used in this 
study) Ti suspension contained approximately 6 x 107 particles/ml. Ti particles were 
stored in Dulbecco’s modified minimal essential medium (DMEM) at 4OC. 
 
Patients and tissue samples 
The collection of human samples from joint replacement and revision 
surgeries, and the use of bone marrow aspirates, were approved by the Institutional 
Review Board; and samples were collected in consent with the patient. Although the 
major focus of this study was the interface membrane fibroblast (IFM-Fb) response 
to bioactive compounds released by cells of the interface membrane, synovial 
samples from normal joints (negative control) and rheumatoid joints (positive 
control) were also collected and tested in preliminary and comparative experiments. 
Normal synovial tissue samples were collected from the knee and ankle joints of 5 
organ donors (age range 28-62 years) within 3-6 hr after death due to cardiovascular 
insufficiency or traffic accident. Additional “normal” synovial tissue samples were 
obtained from patients with femoral neck fractures with no evidence of synovial 
reaction and/or cartilage damage on histologic or radiographic analysis. Finally, a 
total of 12 normal synovial tissue samples were used for gene expression and 
cytokine assays. Synovial tissue from the knee joints of 8 patients with rheumatoid 
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arthritis (RA) (mean age 60.2 years, range 47–63 years) who underwent primary TJA 
surgery was collected. Periprosthetic interface membranes from loosened joint 
replacements (23 hip and 9 knee replacements) with osteolysis were obtained from 
patients during revision surgery, which took place an average of 10.1 years after the 
primary TJA. This group of patients consisted of 18 men and 14 women, with a mean 
age of 62.2 years (range 34–91 years). In addition to focal or diffuse osteolysis, the 
major reasons for revision surgery were pain, limited range of motion, and 
instability. The types of prosthesis and surgical procedure varied, as did the source of 
the tissue (from revision surgeries of hip or knee TJAs) and the original diagnosis 
that led to joint abnormalities and TJA (RA or osteoarthritis [OA]). 
 
Explant cultures and conditioned media (CM) 
Tissue samples in sterile containers of DMEM and 150 µg/ml gentamicin 
were transported from the operating room to the laboratory within 5-20 min after 
removal. Samples were minced (2-4 mm3 in volume) in serum-free DMEM, washed, 
and representative tissue samples were distributed for explant cultures, RNA and 
fibroblast isolation, and histologic examination (Fig. 1D).  
Approximately 0.5g wet synovial or interface membrane tissue was cultured 
in 2.5 ml DMEM containing 5% endotoxin-free fetal bovine serum (FBS, HyClone, 
Logan, UT), antibiotic/antimycotic solution, which was supplemented with 50 µg/ml 
gentamicin. Tissue samples were distributed in 12-well plates, and 90% of the 
medium was replaced daily for a total of seven days (26,27). Media which were 
harvested every 24 hours were centrifuged at 2500g for 10 min, and aliquots were 
reserved for cytokine assays, and stored at –20OC until the explant culture system 
was completed. DMEM containing 5% FBS without tissue samples (medium control) 
was also incubated for 24 hours at 37OC, harvested, centrifuged, and stored in the 
same manner as all other conditioned media.  
 
Fibroblast isolation 
Fibroblasts were isolated from both fresh tissues and 7-day-old explant 
cultures of synovial tissues to compare the yield and viability of fibroblasts from the 
corresponding tissue samples. Fibroblasts were isolated by pronase and collagenase 
digestions as described (19,20). Dissociated cells were washed with PBS and plated 
in Ø10cm petri dishes (Beckton Dickinson, Franklin Lakes, NJ) in DMEM/10% 
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FBS. Non-adherent cells were discarded the next morning by washing, and adhered 
cells (mostly fibroblasts) were cultured in DMEM/10% FBS. The yield of fibroblasts 
varied from sample to sample, but approximately the same number of viable cells 
(85-95%, determined by trypan blue exclusion test) were isolated from the fresh 
tissue and 7-day-old explant cultures.  
Medium from fibroblast cultures was changed twice a week. Confluent 
monolayer fibroblast cultures were passaged at least five times and then passaged at 
~0.7 x 106 cell density per Ø10cm petri dish for experiments. The fibroblast 
phenotype of isolated cells was confirmed by flow cytometry analysis 
(FACSCalibur, CellQuest software program, Beckton Dickinson) using anti-CD90 
(Thy-1) (28) monoclonal antibody (mAb) (BD Pharmingen/ Bioscience, San Diego, 
CA) and by immunohistochemistry in 8-well chamber slides (Nalgene) using 
fluorochrome-labeled mAb 5B5 to F-subunit of propyl-4-hydroxylase (Dako 
Corporation, Carpenteria, CA). Alexa Fluor® 546 phalloidin (Molecular Probes, 
Eugene, OR), which binds to F-actin filaments was used to contour the intracellular 
localization of phagocytosed particles.  
Freshly isolated fibroblasts from interface membranes contained particles 
(Fig. 5A), whereas the number of particles diminished during subsequent passages. 
After three-four passages the presence of particles was rare, and we could not detect 
macrophages or cells of the monocyte/macrophage lineage (CD11b+ cells)(BD 
Pharmingen) with flow cytometry; 99-100% of the cells were CD90+ fibroblasts. To 
mimic the in vivo condition and to determine whether fibroblasts could indeed 
phagocytose particulate wear debris in vitro, fibroblasts isolated from the IFM were 
treated with Ti particles (0.075%, v/v) and passaged into a chamber slide the next 
day. As shown in Figure 4B and 5B, in vitro cultured fibroblasts phagocytosed a 
substantial number of Ti particles.  
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Figure 5. Interface membrane fibroblasts with phagocytosed particles  
A, Images of the same freshly isolated fibroblast from an interface membrane. A1, Phase-contrast 
image. A2 and A3, Fibroblast cultures double-stained with fluorescein isothiocyanate (FITC)–labeled 
monoclonal antibody to fibroblastspecific CD90 (green for surface staining) (A2) and Alexa Fluor 546 
phalloidin (red for actin) (A3). Confocal z-series were projected into a single image to demonstrate the 
intracellular localization of 1 large and a few smaller particles in the interface membrane fibroblast. 
Arrows show metal particles; arrowheads show nuclei.  
B, Fibroblast culture (after 5 passages) exposed to titanium particles overnight (0.075% [v/v]). 
Nonphagocytosed particles were washed out, and cells were stained with crystal violet for light 
microscopy. Arrowheads show nuclei; arrows show phagocytosed particles.  
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Treatment of fibroblasts with CM, Ti particles, or both 
Confluent fibroblast cultures were subjected to 5% FBS containing DMEM 
for 24 hr, and then this medium was replaced with either DMEM with 5% FBS pre-
incubated at 37OC in CO2 incubator (medium control) or conditioned media (without 
dilution) with or without titanium particles for different time periods. We 
simultaneously tested fibroblasts derived from 2 normal, 2 rheumatoid, and 3 
osteoarthritic synovial tissue samples, and data in this report summarize the 
responses of 2–4 independent fibroblast lines isolated from interface membranes. In 
preliminary experiments, we determined the minimum and maximum concentrations 
of conditioned media harvested from interface membrane explant cultures, and the 
“optimal” concentration of titanium particles. Undiluted conditioned media and 
0.075% (v/v) titanium particle concentrations were selected to achieve an average, 
usually the maximum, dose-dependent effect on fibroblast stimulation determined in 
the present study and previous experiments (19). Culture media were collected from 
all particle-stimulated and non-stimulated fibroblast cultures at various time points 
(from 6 hours to 96 hours).  
Finally, we selected 16 conditioned media from the 32 explant cultures of 
interface membranes (CM-IFMs). The presence of particle wear debris in the the 
interface membrane tissues was retrospectively confirmed histologically. Prior to the 
experiments on fibroblast stimulation, conditioned media from interface membranes 
were individually pretested for 48 hours for cytokine production in cultures using the 
same normal synovial fibroblast cell line. The major selection criteria were that these 
conditioned media from interface membranes contained the highest and comparable 
amounts of proinflammatory cytokines and chemokines, and induced approximately 
the same amounts of IL-6, VEGF and IL-1β. Based on the response of this normal 
synovial fibroblast cell line (cytokine production), 4 groups were formed, each 
containing 2–5 conditioned media from interface membranes. These conditioned 
media from interface membranes were pooled and filtered through a 0.22 µm 
polycarbonate filter (Costar, Cambridge, MA), divided into aliquots, stored at –80OC. 
Each of these four pools were then tested at least 2, usually 3-4, independent 
interface membrane fibroblast cell lines (with and without titanium particles), and the 
results are summarized in this study.  
To investigate whether the source of donor tissue (the interface membrane) 
may affect fibroblast response, each pool of the conditioned media was prepared so 
 20
that the interface membranes were derived from patients who underwent TJA either 
due to rheumatoid arthritis (1 group) or osteoarthritis (3 groups), and who had the 
primary TJA 6–9 years prior to the revision surgery. 
The other 16 conditioned media from interface membranes either did not 
fulfill the selection criteria, or the volumes were insufficient for complete 
experiments.  
We have also used fibroblast cell lines derived from normal (n=2) and 
rheumatoid (n=2) synovium. The responses of these cells to either conditioned media 
or titanium, or both, were comparable with those found in interface membrane 
fibroblast cultures after 5–6 passages of cells (results not shown).  
 
In vitro osteoclastogenesis assay 
Bone marrow aspirates were obtained from either iliac crest or vertebral 
bodies from men and women (age range 28–57 years) undergoing spine fusion 
procedures. Culture conditions, isolation and characterization of cells were the same 
as previously described (13,29), except that these bone marrow-derived progenitor 
cells were used for osteoclast formation. Briefly, buffy coat-separated nucleated bone 
marrow cells (2 x 107 per T75 tissue culture flasks) (Corning Inc., Corning, NY) 
were cultured in alpha-minimal essential medium (GIBCO Invitrogen Corporation, 
Carlsbad, CA) containing 10% FBS for 12-24 hours, and then adherent cells were 
gently trypsinized and transferred to 4-well chamber slides (Nalgene Nunc 
International, Naperville, IL) precoated with semiconfluent layer of interface 
membrane fibroblasts that had been left untreated, or pretreated with titanium, TNF-
α or conditioned media from interface membranes.  
Osteoclastogenesis in these cocultures was induced by adding 50 ng/ml 
recombinant macrophage colony stimulating factor (M-CSF; R&D Systems 
Minneapolis, MN) for 8-14 days. Fibroblasts were stained for CD90 and RANKL, 
fluorescent images were stored, and then restained for tartarate-resistant acid 
phosphatase (TRAP, Sigma). Multinucleated (> 4 nuclei per cell) TRAP+ cells were 
counted. Unstimulated interface membrane fibroblasts, interface membrane 
fibroblasts stimulated with M-CSF alone, interface membrane fibroblasts stimulated 
with RANKL alone, or bone marrow cells treated with M-CSF alone were used as 
negative controls. Bone marrow cells treated with M-CSF (50 ng/ml) plus RANKL 
(100 ng/ml; R&D Systems) were used as positive controls. Additionally, fibroblasts 
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were plated (5 x 104 cells/well in a 24-well plate) and pretreated with titanium 
particles (0.075% [v/v]) for 48 hours, and then particulate wear debris was removed 
by exhaustive washing. Subsequently, fresh bone marrow cells (0.8 x 106/well) and 
50 ng/ml M-CSF were added to multiple wells. Fibroblasts alone, bone marrow cells 
alone, fibroblasts and bone marrow cells together, with or without M-CSF, or 
untreated fibroblasts (as described above) were used as negative control cultures. 
 
RNA isolation and RNase protection assay (RPA) 
Fresh tissue samples (~0.2-0.4g), and tissue samples cultured for 7 days, were 
homogenized on ice with a polytron homogenizer (KRI Works, Cincinnati, OH). 
Homogenate was centrifuged to remove large debris, and RNA was extracted with 
TRIzol (Invitrogen) as previously described (13,19). TRIzol was also used to isolate 
total RNA from cultured fibroblasts before and after treatments with titanium, 
conditioned media, or titanium plus conditioned media at 6, 12, 24, 48, and 72 hours. 
The amount of RNA was determined using a RiboGreen RNA quantification kit 
(Molecular Probes) (13).  
RPA was performed on 8 µg of RNA using the Riboquant Multiprobe RNase 
Protection Assay System, according to the recommendations of the manufacturer 
(BD PharMingen). In addition to commercially available cytokine, chemokine, and 
growth factor templates (BD Biosciences) mostly used in preliminary studies and for 
the selection of cytokines and chemokines, 2 custom-made RPA templates were 
purchased from BD PharMingen/Biosciences. The no. 65184 custom-made template 
was designed to quantify the expression levels of human TNF-α, IL-1 receptor type I, 
IL-4, matrix metalloproteinase-1, IL-1α, IL-1β, MCP-1, transforming growth factor-
β1 (TGF-β1), TGFβ receptor type I, and interferon-γ; and template no. 65120 was 
designed to determine a set of angiogenic factors, such as RANTES, interferon-γ-
inducible 10-kD protein, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), 
basic fibroblast growth factor, fibroblast growth factor receptor, IL-8, angiopoietin 1, 
VEGF, and c-myc. Custommade templates included housekeeping genes L32 and 
glyceraldehyde-6-phosphate dehydrogenase (GAPDH). 
Single-stranded labeled ([E-32P]UTP) antisense RNA probes were 
synthesized by in vitro transcription from a complementary DNA (cDNA) template 
provided in the Riboquant Multiprobe RNase Protection Assay kit. Antisense RNA 
probe was purified by phenol–chloroform extraction and ethanol precipitation and 
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was hybridized with messenger RNA (mRNA) samples overnight at 56OC. RNase A 
and RNase T were used to digest nonhybridized single-stranded RNA. Protected 
double-stranded RNA was purified by phenol–chloroform extraction followed by 
ethanol precipitation, and then the 32P-labeled samples of different lengths were 
separated on 5% denaturing polyacrylamide/8M urea gel, as previously described 
(30). Radioactivity of the samples was measured and analyzed by scanning 
densitometry on a Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA). I 
found a high correlation (> 95%) between the amount of ribosomal RNA and the 
message levels of the housekeeping genes L32 and GAPDH. However, L32 
expression was more consistent in titanium-stimulated fibroblast cultures, and all 
samples were normalized to L32. 
 
Reverse transcription real-time quantitative polymerase chain reaction (QRT-
PCR) 
Since neither RANKL nor OPG probe for RPA template was available at the 
time of these experiments, the mRNA levels of these compounds were determined by 
real-time quantitative PCR using the Smart Cycler System (Cepheid, Sunnyvale, 
CA). The detection was carried out by measuring the binding of fluorescent SYBR 
Green-I to double stranded DNA. The PCR reactions were carried out in microtubes 
in 25 µl volume. Real-time quantitative PCR efficiencies for all probes were 
confirmed using three different template dilutions in all of the runs. The cDNA 
template in 1 µl reverse transcriptase PCR product (equivalent with ~0.025-0.1 µg 
total RNA) was added to a PCR mixture which contained final concentrations of 0.5 
µM RANKL-specific forward primer (5’-CGT TGG ATC ACA GCA CAT CAG) 
and reverse primer (5’-GCT CCT CTT GGC CAG ATC TAA C) or OPG-specific 
forward primer (5’-GCA GCG GCA CAT TGG AC) and reverse primer (5’-CCC 
GGT AAG CTT TCC ATC AA), a 1:50,000 dilution of SYBR Green-I stock 
solution (BioWhitaker Mol. Appl. Cambrex, Rockland, ME), 200 µM dNTP, 1.5 mM 
MgCl2, and 2.5 units of Taq DNA polymerase (Promega, Madison, WI). For 
normalization, L32 cDNA was amplified with forward primer (5’-CAA CAT TGG 
TTA TGG AAG CAA CA) and reverse primer (5’-TGA CGT TGT GGA CCA GGA 
ACT). 
The fluorescence emitted by the reporter dye was detected online in real-time, 
and the threshold cycle (Ct) of each sample was recorded as a quantitative measure 
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of the amount of PCR product in the sample as previously described (31). The 
RANKL and OPG signals were normalized against the quantity of L32 and 
expressed as ∆Ct = CtRANKL - CtL32). The differences in RANKL signals were 
expressed as ∆∆Ct = ∆CtTreated – ∆CtUntreated in all different treatment groups. Relative 
gene expressions were than calculated as 2-∆∆Ct.  
The real-time PCR assays were repeated 3 times using 3 independent reverse-
transcribed RNA samples isolated from 3 untreated fibroblast cultures and the 3 
corresponding fibroblast cultures treated with either titanium particles, conditioned 
media from interface membranes, or both, at each time point. The same RNA 
samples that were used for reverse transcription were also used for RPA.  
 
Detection of specific protein products by enzyme-linked immunosorbent assay 
(ELISA) 
All conditioned media harvested from explant cultures of synovial tissues and 
interface membranes, and from treated and untreated fibroblasts after 6–96 hours, 
were analyzed by ELISA. Conditioned media were harvested, centrifuged, and 
aliquots were stored at –70OC. Levels of TNF-α, IL-1β, MCP-1, IL-6, IL-8, and 
VEGF were determined using capture ELISAs (R&D Systems Minneapolis, MN).  
 
Detection of RANKL by Western blot hybridization and flow cytometry 
To detect soluble forms of RANKL, the most potent osteoclastogenic and 
activation factor produced by fibroblasts treated with titanium or conditioned media 
from interface membranes, the harvested tissue culture media were loaded on sodium 
duodecyl sulfate (SDS)-10% polyacrylamide gels (PAGE) under reducing 
conditions. To detect nonsecreted (possibly membrane-bound) RANKL, treated and 
untreated cells were lysed in ice-cold lysis buffer (50 mM Tris HCl [pH 8.0], 150 
mM NaCl, 0.1% SDS, and 1% Nonidet P-40) containing protease inhibitors (1 mM 
phenylmethylsulfonyl fluoride and 1 unit/ml aprotinin), phosphatase inhibitors (50 
mM NaH2PO4, 10 mM Na-pyrophosphate, 50 mM KF, and 1 mM Na3VO4), and 
0.1% NaN3 for 1 hour at 4OC.  
Cell lysates were cleared by centrifugation, and 15 µg of protein per lane was 
separated by SDS–10% polyacrylamide gel electrophoresis under reducing 
conditions. Proteins were electrophoretically transferred onto nitrocellulose 
membranes (BioRad, Hercules CA), and membranes were blocked with 1% fat-free 
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milk, and stained with anti-RANKL mAb (clone 70513; R&D Systems) or rabbit 
polyclonal antibody (Santa Cruz Biotechnology, San Diego, CA). The 24 and 48 kDa 
bands were identified with recombinant human RANKL (Santa Cruz 
Biotechnology). Enhanced chemiluminesence (Amersham, Arlington Heights, IL) 
was used to detect immune reactions.  
For flow cytometry, untreated or treated confluent fibroblast cultures were 
harvested with enzyme-free cell dissociating buffer (Gibco), and then washed 3 times 
in washing buffer (PBS containing 1% bovine serum albumin). Cells were 
resuspended in 100 µl washing buffer and incubated with 10 ng/µl of mouse anti-
human-RANKL mAb (clone 70513) for 1 hour at 4OC, followed by biotin-labeled 
goat anti-mouse Ig antibody (10 ng/µl; BD Pharmingen). The reaction was developed 
with streptavidin-phicoerythrin (Gibco). Samples were fixed in 2% formalin and then 
analyzed by FACSCalibur using CellQuest software (Becton Dickinson, San Jose, 
CA). An IgG1 isotype control mAb was used to determine nonspecific background 
levels in all experiments.  
 
Statistical analysis 
Descriptive statistics were used to determine group means and standard error 
of the mean (SEM). The Pillai's trace criterion was used to detect multivariate 
significance. Subsequently, the Mann-Whitney U test was performed to compare the 
results of experimental groups. P values less than 0.05 were considered significant. 
All statistical analyses were performed with SPSS/PC+ version 10.1 (SPSS, Chicago, 
IL). 
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RESULTS 
 
Selection of ”bone-resorbing” factors 
In the first set of experiments, synovial tissue samples from normal and 
rheumatoid joints were analyzed and their gene expression levels and corresponding 
cytokine/chemokine secretions were compared to those measured in periprosthetic 
(interface membrane) soft tissues.  
For this purpose, we used standard, commercially available Riboquant 
Multiprobe RPA templates (hCK3, hCK4, hCK26, hCR4, hCR5, hCR6 and hAngio- 
1). After prescreening up-regulated genes on different RPA templates, we selected 
the hCK4 template and designed 2 custom-made templates to measure altered gene 
expressions of interest (Figure 6).  
 
Although a number of cytokines, chemokines, and angiogenic factors were 
measured by ELISA or detected by Western blot hybridization, only the ELISA 
results of TNF-α, MCP-1, IL-1β, IL-6, IL-8 and VEGF are shown (Figure 7C). 
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Figure 6. Effect of titanium (Ti) particles and conditioned media (CM) from interface membranes 
(CM-IFM) on gene expression by fibroblasts isolated from the interface membrane.  
Results shown are from Rnase protection assays using radiolabeled complementary RNA probes from 
untreated interface membrane fibroblasts and interface membrane fibroblasts treated for 48 hours with 
titanium and/or conditioned media, on an hCK4 template and 2 custom-made templates. 32P-labeled 
transcripts of known size were generated by in vitro transcription from RNA templates and were used 
as size markers. Dashes indicate the corresponding gene’s position (occasionally 2 or 3 transcripts can 
be seen), whereas the intensities of bands show the level of mRNA expression.  
Expression of the housekeeping gene L32 correlated (>95%) with 18S ribosomal RNA and was used 
for normalization in all experiments. GAPDH (glyceraldehyde-6-phosphate-dehydrogenase) showed 
more variability in response to treatments; thus, it was not used for normalization. 
Representative panels from >15 hybridization experiments using 3–4 independent interface membrane 
fibroblast lines and 4 conditioned media from interface membranes are shown. 
Abbreviations. Template 65184: TNF-α = tumor necrosis factor-α; IL-1α/β = interleukin-1α/β; IL-
1RI = IL-1 receptor type I; MMP-1 = matrix metalloproteinase-1 (collagenase); MCP-1 = monocyte 
chemoattractant protein 1; TGF-β1 = transforming growth factor-β1; TGF-βRI = TGF-β receptor type 
I; IFN-γ = interferon-γ. Template 65120: RANTES: a CXC chemokine regulated upon activation 
normally T-cell expressed and secreted; IP-10 = CXCL-10 = CXC chemokine = interferon-γ-inducible 
10-kDa protein; Cox-1/2 = cyclooxygenase 1 and 2; bFGF = basic fibroblast growth factor; FGF-R = 
fibroblast growth factor receptor; Ang-1 = angiopoietin-1; VEGF = vascular endothelial growth 
factor; c-myc = oncogene. Template hCK4: MCSF = macrophage colony-stimulatory factor; IL-6 = 
interleukin-6; LIF = leukemia inhibitory factor; SCF = stem cell factor; OSM = oncostatin M.  
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Figure 7. A and B, Steady-state mRNA levels measured in fresh normal synovial tissue (NSy), 
rheumatoid synovial tissue (RASy), and interface membranes (IFM), either freshly isolated (A) or 
after a 7-day culture period (B). C, Secreted cytokine, chemokine, and VEGF levels measured in 
pooled conditioned media of explant cultures. Levels of mRNA were measured by RNase protection 
assay (RPA) normalized to the expression of the housekeeping gene L32 in the same sample, and 
cytokine levels were determined by capture enzyme-linked immunosorbent assay (ELISA). Values are 
the mean and SEM. See Figure 2 for other definitions. 
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Steady-state mRNA levels in interface membrane and synovial tissues, and 
secreted cytokines/chemokines in conditioned media 
As summarized in Figure 7 for selected compounds, normal synovial tissue 
expressed significantly lower message levels for all cytokines, chemokines, growth 
factors and angiogenic factors than did either synovial samples from rheumatoid 
joints or interface membrane tissue samples (Figure 7A). The gene-specific mRNA 
expression continuously increased until day 7, the final day of explant cultures 
(Figure 7B), when the message levels for all measured genes were approximately 4-
10-fold higher than in fresh samples (Figure 7A). These findings corresponded to the 
results of measurement of secreted cytokines and growth factors (Figure 7C). 
 
Selection of fibroblasts and fibroblast activation markers 
Originally, we collected conditioned media from normal and rheumatoid 
synovium, and conditioned media from interface membranes (Figure 7), and tested 
fibroblasts of different origins. IL-1β, MCP-1 and IL-6 seemed to be the most 
sensitive and consistent markers of fibroblast activation. We found slight, but not 
significant, differences in fibroblast responses when the same conditioned media 
(with or without titanium particles) were tested on different fibroblast cell lines.  
Finally, as described in above, 16 conditioned media from interface 
membranes were combined in 4 pools, and these pooled conditioned media were 
tested in 2-4 interface membrane fibroblast cell lines. In addition, we prepared an 
artificial “cytokine cocktail” (used as a positive control) based on the concentrations 
of 6 cytokines/chemokines measured in conditioned media from interface 
membranes (Figure 7C).  
With this cocktail, we observed similar levels of IL-6, IL-1β, and MCP-1 
secretion by interface membrane fibroblasts as were found when conditioned media 
from pathologic samples (either rheumatoid synovium or interface membrane) were 
used (Figure 8).  
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Figure 8. Expression of mRNA for IL-1β, MCP-1, and IL-6 in interface membrane fibroblasts 
cultured for 24 hours in normal Dulbecco’s minimum essential medium with 5% fetal bovine serum, 
and in conditioned media harvested from explant cultures of normal synovial tissue (CM-NSy) and 
rheumatoid synovial tissue (CM-RASy), interface membranes from loosened implants (CM-IFM), and 
a “cytokine cocktail” containing 3 pg/ml TNF-α, 80 pg/ml IL-1β, 150 ng/ml IL-6, 300 ng/ml IL-8, 20 
ng/ml VEGF, and 50 ng/ml MCP-1. This cocktail concentration was selected to represent 
approximately the same cytokine/chemokine and VEGF concentrations that were measured in pooled 
CM-IFM (Figure 3C). In general, the combination of titanium (Ti) and CM-IFM had a synergistic 
effect. TNF-α and IL-1β, when used alone, exerted the highest effect on MCP-1 and IL-6 expression 
after 48 hours of treatment. Findings with all treatments were normalized to L32 expression. Values 
are the mean and SEM of 9–15 RNase protection assays (RPAs) (48-hour treatments using 3–4 
interface membrane fibroblast lines). * = P < 0.05; ** = P < 0.01, versus untreated samples. Lower 
panels show strips of representative RPA membranes using the same interface membrane fibroblast 
line. See Figure 6 for other definitions.  
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Expression of mRNA and secretion of proteins by fibroblasts exposed to 
titanium particles, conditioned media from interface membranes, or both 
We showed that fibroblasts could phagocytose particles either in vivo (Figure 
5A), or in vitro (Figure 4B and 5B), and that fibroblasts responded to stimulation 
with titanium particles, inflammatory cytokines, and conditioned media (Figure 8). 
The response was observed at both the transcriptional and the translational levels. 
Therefore, we were interested in (1) correlations between titanium-induced and 
conditioned media–induced gene expression, (2) the level and time frame of 
titanium-induced and conditioned media–induced gene expressio, and (3) which of 
the genes that code for the most relevant bone-resorbing agents are significantly 
affected by stimulation with either titanium particles or conditioned media. To 
investigate these gene characteristics, interface membrane fibroblasts were left 
untreated (i.e., cultured in medium control), or treated with conditioned media from 
interface membranes with or without 0.075% (v/v) titanium particles. Titanium 
particles had an effect, but relatively moderate one, on the expression of genes 
selected on the 3 RPA templates (Figure 6). Among the genes differentially 
expressed in the cultures treated with conditioned media from interface membranes 
versus the untreated cultures, MCP-1, IL-6, IL-8, TGFβ1, VEGF, Cox-1, and Cox-2 
were the most prominently expressed.   
These genes were expressed at even higher levels with combination treatment 
(conditioned media from interface membranes plus titanium). 
Titanium particles and conditioned media from interface membranes 
exhibited either additive or synergistic effects on MCP-1, IL-8, Cox-2, IL-6 and 
leukemia inhibitory factor (LIF), all of which are known to be involved in osteoclast 
maturation and activation (Figure 6).  
 
Interface membrane fibroblasts responded to treatment in both a dose-
dependent manner (data not shown) and a time-dependent manner.  
In general, with the 3 selected fibroblast activation markers (IL-1β, MCP-1 
and IL-6) the highest gene expression was achieved between 12 and 48 hours of 
treatment, whereas the highest amounts of secreted proteins (except IL-1β) were 
measured in culture media between 72 and 96 hours (Figure 9). 
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Figure 9A. Time-dependent responses of interface membrane fibroblasts to stimulation with 
conditioned media from interface membranes (CM-IFM) in the presence or absence of titanium (Ti) 
particles (0.075% [v/v]). Left panel summarizes the expression of mRNA for IL-1β, and right panel 
shows levels of the corresponding proteins secreted into the medium. IL-1β levels represent the 
amount of proteins actually secreted (their “original” concentrations in the CM-IFM [incubated 
without fibroblasts] have been subtracted). Note the picogram levels of IL-1β. Values are the mean ± 
SEM of triplicate wells from 3–5 independent experiments. See Figure 6 for other definitions. 
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Figure 9B. Time-dependent responses of interface membrane fibroblasts to stimulation with 
conditioned media from interface membranes (CM-IFM) in the presence or absence of titanium (Ti) 
particles (0.075% [v/v]). Left panel summarizes the expression of mRNA for MCP-1, and right panel 
shows levels of the corresponding proteins secreted into the medium. MCP-1 levels represent the 
amount of proteins actually secreted (their “original” concentrations in the CM-IFM [incubated 
without fibroblasts] have been subtracted). Note the nanogram levels of MCP-1. Values are the mean 
± SEM of triplicate wells from 3–5 independent experiments. See Figure 6 for other definitions. 
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Figure 9C. Time-dependent responses of interface membrane fibroblasts to stimulation with 
conditioned media from interface membranes (CM-IFM) in the presence or absence of titanium (Ti) 
particles (0.075% [v/v]). Left panel summarizes the expression of mRNA for IL-6, and right panel 
shows levels of the corresponding proteins secreted into the medium. IL-6 levels represent the amount 
of proteins actually secreted (their “original” concentrations in the CM-IFM [incubated without 
fibroblasts] have been subtracted). Note the nanogram levels of IL-6. Values are the mean ± SEM of 
triplicate wells from 3–5 independent experiments. See Figure 6 for other definitions. 
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M-CSF, OPG and RANKL expression by interface membrane fibroblasts in 
response to stimulation 
Fibroblasts of interface membranes expressed mRNA for VEGF, M-CSF 
(Figure 6), OPG and RANKL (Figure 10) in response to treatment with conditioned 
media from interface membranes or treatment with conditioned media from interface 
membranes plus titanium.  
 
These cells also spontaneously secreted/shed the 24 kDa soluble form of 
RANKL, and expressed the 48 kDa membrane-bound form of RANKL (32), 
especially after stimulation (Figure 10).  
 
Since both OPG (a decoy receptor of RANKL) and RANKL were detectable 
in conditioned media from interface membranes (results not shown), and 
immunolocalized in different cell types of the interface membrane (21,33), we were 
interested in the capacity of interface membrane fibroblasts to express RANKL. 
Interface membrane fibroblasts were stimulated with conditioned media, IL-1β or 
TNF-α, and RANKL expression was detected by flow cytometry (Figure 11). 
 
Of note, while the expression of OPG peaked after 12 hours of stimulation 
and then significantly declined, the expression of RANKL continuously increased in 
a time-dependent manner (Figure 10). Thus, these osteoclastogenic factors (M-CSF 
and RANKL) were secreted by fibroblasts in response to activation by 
proinflammatory cytokines, and their levels were further increased in the presence of 
titanium particles. The combination of conditioned media from interface membranes 
and titanium particles had a synergistic effect on the expression of RANKL (Figure 
10). 
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Figure 10. Expression of M-CSF, osteoprotegerin (OPG), and RANKL by interface membrane 
fibroblasts after 12- or 48-hour treatment with titanium particles and/or conditioned media from 
interface membranes (CM-IFM). Expression of mRNA for M-CSF was measured by RNase 
protection assay, and expression of mRNA for OPG and RANKL was measured by real-time 
polymerase chain reaction. Values are the mean and SEM of 6–12 measurements. * = P < 0.05; ** = 
P < 0.01. Representative Western blot panels show secreted/shed RANKL in medium harvested from 
fibroblast cultures (24-kDa band), and membrane-bound RANKL from fibroblast cell lysates (48-kDa 
band). Recombinant human RANKL (rhRANKL) was used as a positive control.  
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Figure 11. Expression of RANKL by interface membrane fibroblasts after treatment with TNF-α, IL-
1β, or conditioned media from interface membranes (CM-IFM).  
The panel summarizes flow cytometry results, when interface membrane fibroblasts were stimulated 
for 24 hours (as indicated) or left untreated (Untr), and then stained with mouse monoclonal antibody 
(clone 70513; R&D Systems) for RANKL expression. See Figure 6 for other definitions. 
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Induction of osteoclastogenesis by fibroblast-derived factors in the presence of 
M-CSF   
Since conditioned media from interface membranes, especially in the 
presence of titanium wear debris, induced significant expression of RANKL by 
fibroblasts, we established a coculture of human interface membrane fibroblasts and 
bone marrow-derived stromal cells. These bone marrow-derived stromal cells 
differentiated to multinucleated TRAP+ cells in the presence of M-CSF and RANKL 
(Figure 12A), but not in the absence of either of these compounds.  
 
Similarly, bone marrow-derived stromal cells that had been cocultured with 
titanium-stimulated interface membrane fibroblasts (in the presence of M-CSF) 
differentiated into TRAP+ multinucleated cells (Figure 12B), but bone marrow–
derived stromal cells never differentiated into TRAP+ multinucleated cells in 
unstimulated fibroblast cultures or in the absence of M-CSF (results not shown).  
 
Interface membrane fibroblasts activated with either conditioned media from 
interface membranes (cytokines) or titanium wear debris continuously expressed 
RANKL, which could then induce osteoclastogenesis in the presence of M-CSF. 
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Figure 12. Interface membrane fibroblasts cocultured with human bone marrow cells. 
A, Interface membrane conditioned media–stimulated interface membrane fibroblasts and bone 
marrow–derived stromal cells cocultured for 12 days in the presence of 50 ng/ml macrophage colony-
stimulating factor (M-CSF). Fibroblasts were stained first for RANKL with FITC-labeled antibody. 
Arrows show multinucleated cells positive for tartrate-resistant acid phosphatase (TRAP), identified 
on a hematoxylin-counterstained slide. The 2 corresponding images were overlaid to reconstitute the 
original coculture condition.  
B, Fourteen-day coculture of interface membrane fibroblasts and human bone marrow cells. After 10 
passages, fibroblasts (5X104 cells/well in a 24-well plate) were treated with titanium particles (0.075% 
[v/v]) as described in Materials and Methods. Other culture wells contained either fibroblasts or bone 
marrow cells, or both, with or without titanium pretreatment or M-CSF. Multinucleated TRAP+ cells 
were identified only in wells that contained titaniumpretreated fibroblasts, bone marrow cells, and M-
CSF. Arrowheads show 3 nuclei of a multinucleated TRAP-stained cell; arrows show phagocytosed 
titanium particles, which are present in both fibroblasts and multinucleated cells. 
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DISCUSSION 
 
Approximately 30% of periprosthetic soft tissue (interface membrane) is 
composed of fibroblasts (3,34,35), and these cells have the highest proliferation rate 
in the interface membrane (16,36), indicating their activated state (37). Proliferation 
of fibroblasts and vascular endothelial cells in the periprosthetic tissue reflects active 
tissue remodeling, wherein interface membrane soft tissue replaces the resorbed bone 
around the prosthetic device. In this particular milieu, different cells and particulate 
wear debris maintain an endless activation stage, leading to the loosening and failure 
of joint arthroplasties, which is frequently accompanied by clinically evident 
periprosthetic osteolysis. 
In previous studies we and others showed that IFM fibroblasts were highly 
activated in situ (especially in the bone resorbing areas) (4,36,37), and produced 
factors which suppressed major osteoblast functions (11). We have chosen human 
fibroblasts of the IFM for study since, other than tissue macrophages, this is the 
predominant cell type in the periprosthetic soft tissue (1-4). In order to reproduce the 
in vivo conditions as closely as possible, particles of approximately the same size 
distribution as the wear debris present in periprosthetic tissues were used to simulate 
fibroblasts (6,43,45). In this study we focused upon fibroblast activation in vitro to 
monitor how these cells might be involved in pathological bone resorption.  
We have shown, by RPA, the overexpression of several “osteoclastogenic” 
factors (VEGF, MCP-1, M-CSF, COX-1, COX-2, and LIF) by human interface 
membrane fibroblasts. In addition, real-time quantitative PCR demonstrated 
overexpression of RANKL and OPG. Cells of this periprosthetic soft tissue, 
including fibroblasts, are under strong activation pressure due to continuously 
generated particulate wear debris, which maintains a chronic state of inflammation 
(26,36,38,39).  
Fibroblasts are actively involved in this detrimental process in that 1) they are 
continuously stimulated by both prosthetic wear debris and cytokines/growth factors 
produced by activated macrophages, osteoblasts, and fibroblast-secreted products, 2) 
they suppress osteoblast functions, and 3) they directly or indirectly contribute to 
osteoclast activation (19,21,22,33,40) (Figures 12A and B). 
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To gain insight into the complex mechanisms taking place in the 
periprosthetic space and to understand how these fibroblasts are involved in 
osteolysis, we (in the present study) and others (21,22,34,39,41,42) have used 
fibroblasts from different sources (synovial tissue of normal and pathologic joints, 
and interface membranes) and tested their responsiveness under different conditions. 
In this study, we examined the responsiveness of human fibroblasts of different 
origins to titanium particles and conditioned media harvested from synovial tissue 
from normal and rheumatoid joints or from interface membranes. Using the same 
conditioned media from interface membranes, stimulation of fibroblasts from normal 
synovial tissue (up to 3–5 passages) was less effective than stimulation of fibroblasts 
isolated from rheumatoid synovium or interface membranes, although the difference 
was not significant. In contrast, stimulation with conditioned media from normal 
synovial tissue had minimal or no effect on fibroblasts isolated from either normal or 
pathologic (e.g., interface membrane) tissue. Thus, while the in vitro response levels 
of fibroblasts derived from either a normal or an inflammatory milieu were highly 
comparable after a few passages, cells from inflamed tissue (rheumatoid synovium or 
interface membrane) produced significantly more bioreactive compounds in vitro 
than cells obtained from normal synovial tissue. 
To mimic the in vivo conditions of periprosthetic pathologic bone resorption 
as closely as possible, we stimulated interface membrane fibroblasts with titanium 
particles and/or conditioned media from interface membranes. In order to reproduce 
in vivo conditions, particles of approximately the same size distribution as the wear 
debris present in periprosthetic tissue (6,43–45) were used to stimulate fibroblasts. In 
general, fibroblasts from interface membranes with various degrees of osteolysis 
responded very similarly after 4–6 passages, but the variability of 
cytokine/chemokine concentrations in collected conditioned media (Figure 7C) had 
a more diverse effect on fibroblast activation. Therefore, we selected a model system 
in which we could compare activation events in several fibroblast lines, using 
conditioned media from a number of interface membranes with high levels of TNF-
α, IL-1β, IL-6, IL-8, MCP-1, and VEGF, factors that are involved in 
osteoclastogenesis. 
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We found that MCP-1 was as good a marker of fibroblast activation as IL-6, 
and that both of these secreted compounds had an effect on osteoclast activation, 
although this effect was indirect (46). While fibroblasts express both tumor necrosis 
factor receptor p55 (TNFR p55) and TNFR p75 (41,46) and respond to TNF-α 
stimulation (Figure 8), neither synovial nor interface membrane fibroblasts produced 
TNF-α in response to stimulation with titanium particles or conditioned media from 
interface membranes (Figure 6). In contrast, exogenous TNF-α significantly up-
regulated IL-1β, IL-6, and M-CSF expression, and even more dramatically up-
regulated MCP-1 and RANKL expression, in both interface membrane fibroblasts 
(Figures 8 and 11) and synovial fibroblasts (data not shown). Thus, fibroblasts, via 
TNFR p55, might be involved in both RANKL-dependent and RANKL-independent 
osteoclastogenesis (47), and the therapeutic effects of various anti-TNF therapies 
(48,49) may, at least in part, be associated with these mechanisms. This observation 
suggests that activated fibroblasts, upon exposure to particles and/or 
proinflammatory cytokines (TNF-α and IL-1β) produced by adjacent cells in the 
interface membrane, secrete large amounts of chemokines (such as MCP-1 and IL-8), 
thereby recruiting cells of the myeloid lineage. 
Among the fibroblast activation markers induced by either TNF-α, IL-1β, 
particulate titanium, or conditioned media from interface membranes, the expression 
of membrane-bound RANKL, a potent osteoclastogenic mediator, together with 
soluble forms of RANKL (24 kDa and lesser amounts of 27.6 kDa) (Figure 10-11) 
was detected. In addition, activated fibroblasts secreted VEGF (Figure 6 and 7C) 
and M-CSF (Figures 6 and 10), which are also needed for osteoclastogenesis 
(46,50–52). Therefore, many of the osteoclastogenic factors detected in the interface 
membrane (21,53,54) might derive from activated fibroblasts (Figure 7), but they are 
less likely derived from RANKL+ activated T or B cells (46), which are rare in the 
interface membrane. 
RANKL-expressing osteoblasts, and especially fibroblasts that express RANKL, are 
purportedly primarily responsible for osteoclast differentiation and activation 
(21,22,33,46,54) and subsequent periprosthetic osteolysis (21,53,54). Osteoblasts, 
however, are rarely seen in the osteolytic areas (4). In contrast, fibroblasts and 
macrophages are present adjacent to osteoclasts (4), and because activated fibroblasts 
secrete RANKL, VEGF, and M-CSF, it may well be that the fibroblast is the key cell 
type moderating osteoclastogenesis in periprosthetic osteolysis.  
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To mimic this in vivo condition in vitro, we used interface membrane conditioned 
media–stimulated or particulate titanium–stimulated interface membrane fibroblasts, 
cells that express RANKL, to induce the formation of multinucleated TRAP+ 
osteoclast-like cells from human bone marrow stromal cells in the presence of M-
CSF (Figure 12). Similar mechanisms have been hypothesized to take place in bone-
resorbing rheumatoid synovium (41,46). 
Taken together, the present results indicate that macrophage activation and fibroblast 
activation are “natural” processes in the interface membrane and rheumatoid 
synovium, and the effect of fibroblast activation on osteoclastogenesis and 
subsequent bone resorption may be as potent and critical as that of macrophage 
activation. In addition, activated fibroblasts produce large amounts of bone-resorbing 
metalloproteinases accompanied by reduced secretion of tissue-specific 
metalloproteinase inhibitors (19), which, together with fibroblast-induced 
suppression of osteoblast function (11), suggests that fibroblasts have a significant 
role in the pathogenesis of periprosthetic osteolysis. 
Of marked importance for future investigation will be the careful analysis of 
retrieved clinical specimens to better characterize the nature of the particulate wear 
debris. The next challenge will be for the biomaterials engineers to produce 
comparable materials for testing in in vitro and in vivo models so that the biological 
properties of these materials can be defined. 
The importance of mechanical factors and material properties in the pathogenesis of 
aseptic loosening of implants has been well established, and these processes clearly 
are essential elements in the complex sequence of events that accompany the failure 
of an implant. Studies provide important insights into how biological processes 
contribute to these events. Although major efforts need to be continued to reduce the 
adverse effects of mechanical factors and to decrease the potential for materials 
failure, an awareness of these biological processes could lead to the development of 
additional therapeutic approaches that will prolong the survival of implants. The 
application of experimental models may allow investigators to evaluate the potential 
efficacy of pharmacological agents in terms of their ability to slow the loosening 
process by selectively inhibiting the mediators of bone resorption that is induced in 
response to particulate debris. Furthermore, this information could contribute to the 
development of alternative methods of fixation of implants that reduce the tendency 
of the implant to generate particulate debris.  
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Alternatives to cement as well as the introduction of different materials and designs 
for the fabrication of implants that have less biological activity, even when particles 
of the prosthesis are released, are potential outcomes of these investigations. It is 
anticipated that an increasing awareness of these biological factors will be used in 
conjunction with the knowledge of mechanical and materials factors, with the 
ultimate goal of delaying or preventing aseptic loosening. 
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THESIS 
 
RESULTS 
 
Fibroblasts phagocytosed particulate wear debris, and responded to 
cytokine/chemokine stimulation. The most dominant compounds measured in CM of 
IFM were tumor necrosis factor-α (TNF-α), monocyte/macrophage chemoattractant 
protein-1 (MCP-1), interleukin-1β (IL-1β), IL-6, IL-8 and vascular endothelial 
growth factor (VEGF). The most prominent upregulated genes, and secreted proteins 
by fibroblasts in response to stimulation were: matrix metalloproteinase-1, MCP-1, 
IL-1β, IL-6, IL-8, cycloxygenases (Cox-1 and Cox-2), leukemia inhibitory factor-1 
(LIF-1), transforming growth factor β-1 (TGF-β1), TGFβ receptor-I and VEGF.  
In addition, IFM fibroblasts expressed RANKL (receptor of activated nuclear factor-
kappa B ligand) and OPG (osteoprotegrin) in response to CM-, TNF-α-, or IL-1β-
stimulation. Particulate titanium stimulated RANKL+ fibroblasts co-cultured with 
bone marrow cells induced osteoclastogenesis. 
 
 
 
CONCLUSION 
 
IFM fibroblasts respond directly to particulate wear debris, possibly via 
phagocytosis, expressing proinflammatory cytokines and RANKL.  
Fibroblasts activated by either particulate wear debris or proinflammatory cytokines, 
are capable of expressing a wide array of osteoclastogenic factors which are involved 
in the detrimental processes of the periprosthetic tissue remodeling and osteolysis. 
These cells are actively involved in diminished bone remodeling and pathological 
(e.g. periprosthetic) bone resorption. 
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